View ValuationUpexi 향후 성장Future 기준 점검 1/6Upexi의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Personal Products 이익 성장8.5%매출 성장률15.1%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트13 May 2026최근 향후 성장 업데이트공시 • Nov 15+ 1 more updateUpexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023Upexi, Inc. revised preliminary and unaudited financial guidance for the first quarter ended September 30, 2023. For the year, the company expects Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.공시 • Sep 30Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023Upexi, Inc. provided revenue guidance for the Fiscal year 2023. For the period, the company estimates baseline annual revenue to be in the range of $72 to $82 million for the full fiscal year.공시 • May 18Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Grove, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company estimated revenue at a range of $16 million to $18 million.모든 업데이트 보기Recent updatesBoard Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • May 06+ 1 more updateUpexi, Inc., Annual General Meeting, Jun 15, 2026Upexi, Inc., Annual General Meeting, Jun 15, 2026. Location: at 3030 n. rocky point drive, suite 420, fl 33607, tampa United States공시 • Feb 10Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million.Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Price\Range: $1.17 Discount Per Security: $0.0585 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offering공시 • Feb 06Upexi, Inc. has filed a Follow-on Equity Offering.Upexi, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offering공시 • Feb 05Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Jan 31Upexi, Inc. to Report Q2, 2026 Results on Feb 10, 2026Upexi, Inc. announced that they will report Q2, 2026 results on Feb 10, 2026공시 • Dec 02Upexi, Inc. announced that it has received $10.000001 million in fundingOn December 2, 2025, Upexi, Inc. announced that it has received $ 10,000,000 in funding from issuance of common stock of the company and closed the transaction. The company raised $10,000,000 upfront with up to an additional $ 13,000,000 of aggregate gross proceeds upon the cash exercise in full of warrants of the company which adds up to $ 23,000,000 in proceeds.공시 • Nov 26Upexi, Inc. announced that it expects to receive $10.000001 million in fundingUpexi, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor for issuance of 3,289,474 common shares at a price of $3.04 per share for gross proceeds of $10,000,000.96; and warrants to purchase up to 3,289,474 common shares on November 26, 2025. The warrants will have an exercise price of $4, will be immediately exercisable, and will expire 48 months from issuance. The closing of the offering is expected to occur on or about December 1, 2025, subject to the satisfaction of customary closing conditions.공시 • Nov 14Upexi, Inc. (NasdaqCM:UPXI) announces an Equity Buyback for $50 million worth of its shares.Upexi, Inc. (NasdaqCM:UPXI) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of it's shares.공시 • Nov 08Upexi, Inc. to Report Q1, 2026 Results on Nov 11, 2025Upexi, Inc. announced that they will report Q1, 2026 results on Nov 11, 2025공시 • Oct 24Upexi, Inc. Welcomes Jon Najarian to the Upexi Advisory CommitteeUpexi, Inc. announced the addition of Jon Najarian to the Upexi Advisory Committee, joining Arthur Hayes and S?L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Market Rebellion, cementing his reputation as a market heavyweight across both professional and retail trading. He is an inductee into the U.S. Options Industry Council Hall of Fame, having received the Lifetime Contribution Award in recognition of his enduring impact on the industry. Beyond his trading acumen, Jon is a prominent media personality, frequently appearing on Fox Business, NewsMax, NewsNation, and other financial platforms, where his market analyses and actionable insights reach millions of investors. With a combination of professional credibility, entrepreneurial success, and exceptional visibility, Jon has emerged as one of the most recognized and trusted voices for both institutional and retail traders navigating complex markets.공시 • Aug 12Upexi, Inc. Announces Establishment of Advisory CommitteeUpexi, Inc. announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek to leverage the expertise, visibility and network of the Advisory Committee by: In conjunction with the establishment of the Advisory Committee, Upexi has welcomed Arthur Hayes (Twitter: @CryptoHayes) as its first member. A former equity derivatives trader at Deutsche Bank and Citigroup, Arthur’s deep financial acumen and bold vision quickly propelled him to the forefront of the digital assets space, where he co-founded BitMEX, one of the world’s largest cryptocurrency exchanges, and revolutionized digital asset trading with the invention of the perpetual swap – the most widely-traded crypto financial product of all time. Arthur is widely regarded as a thought leader whose market insights and macroeconomic commentary are followed closely by investors around the world. His fearless approach to innovation and profound impact on the industry has cemented his legacy as one of the space’s most iconic and respected voices. Additional Advisory Committee members will be announced over the coming weeks, with Committee-related content and initiatives forthcoming over the coming year and beyond. Arthur Hayes is the CIO of Maelstrom, a family office that invests across the crypto ecosystem. He is also the co-founder of BitMEX – the first crypto unicorn. Prior to entering the crypto industry, he worked as a trader in the capital markets divisions of Deutsche Bank and Citibank. Arthur holds a Bachelors of Economics from the Wharton School of Business. He has appeared on major business news networks including Bloomberg and CNBC. He is active on X (@cryptohayes) and releases a monthly newsletter (Crypto Trader Digest) read by thousands of investors globally.공시 • Jul 26Upexi, Inc. announced that it expects to receive $500 million in funding from A.G.P. / Alliance Global Partners Corp.Upexi, Inc announced a private placement and entered into a purchase agreement with A.G.P./Alliance Global Partners to issue common shares for aggregate gross proceeds of $500,000,000 on July 25, 2025. Pursuant to the purchase agreement, the Company shall have the right, but not the obligation, to direct the Investor to purchase the lesser of (i) $500,000,000 or (ii) the Exchange Cap, which shall be the number of shares not to exceed 19.99% of the Company’s shares of common stock, par value $0.00001 per share, outstanding on July 25, 2025, unless the Company’s stockholders have approved the issuance of Common Stock in excess of the Exchange Cap, upon satisfaction of certain terms and conditions contained in the Purchase Agreement, including, but not limited to, an effective registration statement filed with the U.S. Securities and Exchange Commission. The Common Stock will be offered pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) of Regulation D promulgated thereunder, and applicable state securities laws.공시 • Jul 17Upexi, Inc. announced that it has received $199.828744 million in funding from Big Brain HoldingsOn July 17, 2025, Upexi, Inc closed the transaction. The company issued convertible Notes for aggregate gross proceeds of $150,000,000 in its second and final tranche. The transaction included participation from from Big brain Holdings as a lead Investor among other Institutional Investors and qualified purchasers.공시 • Jul 13Upexi, Inc. announced that it expects to receive $49.828744 million in fundingUpexi, Inc. announces that it has entered into securities purchase agreements to issue 12,457,186 shares of common stock at a price of $4 per share for gross proceeds of $49,828,744 on July 11, 2025. The closing of the Equity Offering is expected to occur on or about July 14, 2025.공시 • May 17Upexi, Inc. announced delayed 10-Q filingOn 05/16/2025, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 01Upexi, Inc., Annual General Meeting, Jun 16, 2025Upexi, Inc., Annual General Meeting, Jun 16, 2025. Location: 3030 n. rocky point drive, suite 420, florida 33607., tampa, United States공시 • Apr 26Upexi, Inc. announced that it has received $99.99211 million in funding from GSR, Big Brain, White Star Capital, L.P., Delta Blockchain Fund LPOn April 24, 2025, Upexi, Inc. closed the transaction. The company issued 35,970,383 shares of common stock and 7,889,266 pre-funded warrants at a price of $2.28 per share for aggregate gross proceeds of approximately $100 million.공시 • Apr 21Upexi, Inc. announced that it expects to receive $100 million in funding from GSR, Big Brain, White Star Capital, L.P., Delta Blockchain Fund LP and other investorsUpexi, Inc. announced that it has entered into securities purchase agreements with certain investors to issue 43,859,649 shares of common stock or pre-funded warrants at issue price of $2.28 per share for gross proceeds of $99,999,999.72 on April 21, 2025. The transaction includes participation from lead investor, GSR Markets UK Limited, Big Brain, Anagram, Delphi Ventures, White Star Capital, Maelstrom, the family office of Arthur Hayes, Hivemind, Borderless, Morgan Creek, Elune Capital, and Delta Blockchain Fund, including Austin Federa, Frank Chaparro, Joey Krug, Bartosz Lipinski, Larry Wu, and Jordan Prince, among others including Allan Marshall. The closing of the offering is expected to occur on or about April 24, 2025. The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated thereunder, or applicable state securities laws.공시 • Nov 22Upexi Receives Notice from the Nasdaq Stock MarketUpexi, Inc. received a Non Compliance Letter from The Nasdaq Stock Market LLC due to the Company’s failure to timely file its Form 10-Q Quarterly Report for the period ended September 30, 2024, in violation of Nasdaq Listing Rule 5250(c)(1). The Company failed to timely file due to circumstances beyond its control, and intends to file its Form 10-Q Quarterly Report shortly after it is able to file its Form 10-K Annual Report. Pursuant to the Nasdaq Listing Rules, the Company has until December 20, 2024 to submit a plan to regain compliance. If the plan is accepted, an extension may be granted of up to 180 calendar days from the due date of the Initial Delinquent Filing, or April 14, 2025, to regain compliance. The Notice has no immediate effect on the listing or trading of the Company’s common stock.공시 • Nov 15Upexi, Inc. announced delayed 10-Q filingOn 11/14/2024, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 24+ 1 more updateUpexi, Inc. to Report Fiscal Year 2024 Results on Nov 01, 2024Upexi, Inc. announced that they will report fiscal year 2024 results at 9:30 AM, US Eastern Standard Time on Nov 01, 2024공시 • Oct 03Nasdaq Grants Additional 180 Days to Upexi to Regain Compliance with Minimum Bid Price RequirementUpexi, Inc. received a letter from The Nasdaq Stock Market LLC (Nasdaq") indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company's common stock (the Common Stock") had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance. The Common Stock did not regain compliance with the Minimum Bid Price Requirement within such period. The Company timely requested, and was granted by Nasdaq on October 1, 2024, an additional 180 calendar days to regain compliance with the Minimum Bid Price Requirement.공시 • Oct 01Upexi, Inc. announced delayed annual 10-K filingOn 09/30/2024, Upexi, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Aug 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Aug 07David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million on August 1, 2024. A cash consideration of $2 million will be paid by E-Core Holdings, LLC. The purchase price in the transaction was $2 million. In addition, in connection with the closing of the transaction (i) Upexi, Inc. was released as a guarantor from E-Core, Inc’s commercial loan facility, and (ii) all subordinated promissory notes issued by Upexi, Inc. in connection with the Upexi, Inc.’s initial acquisition of E-Core, Inc were cancelled and any outstanding principal and interest thereunder was deemed paid in full. On the Closing Date, (a) each Transaction Document shall be deemed null and void, and all obligations of the parties thereunder shall terminate; (b) Upexi Newco shall assign and transfer back to Upexi Newcos all of E-Core Newco’s right, title and interest in and to 4,000 shares of common stock of E-Core purchased from Upexi Newco in the Transaction (the “ E-Core Shares ”), constituting all of E-Core’s issued and outstanding securities, free and clear of any liens or encumbrances; and (c) the Consideration shall be paid in full by the Parties. Dickinson Wright PLLC acted as legal advisor to Upexi, Inc. and Korn & Kalish LLP acted as legal advisor to David Romano, Nick Romano and Eric Limont. David Romano, Nick Romano and Eric Limont completed the acquisition of E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) on August 1, 2024.공시 • Jun 22Upexi Provides Update on Filing Form 10Q for March 31, 2024Upexi, Inc. (the Company" or Upexi") is providing shareholders with a update on filing its financial statements for the three and nine months ended March 31, 2024. On June 17, 2024, the Company received a notice from Nasdaq Listing Qualifications that since the Company has not yet filed its Form 10-Q for the period ended March 31, 2024 (the Filing"), it no longer complies with our Listing Rules (the Rules") for continued listing. Under the Rules the Company now has 60 calendar days to submit a plan to regain compliance and if we accept your plan, we can grant an exception of up to 180 calendar days from the Filing's due date, or until December 11, 2024, to regain compliance. Upexi management has discussed this with the Nasdaq and expects to file the form 10-Q for the period ended March 31, 2024 prior to the end of June 30, 2024 and once this is filed, a plan will not be necessary to regain compliance. The Nasdaq Notice Letter has no immediate effect on the listing or trading of the Company's common stock.공시 • Jun 21Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024Upexi, Inc. announced that they will report Q3, 2024 results on Jun 24, 2024공시 • Jun 18MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million on June 13, 2024. A cash consideration of $4 million will be paid by MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC. MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC will pay an earnout/contingent payment of $1 million promissory note and of $1 million cash. As part of consideration, $6 million is paid towards common equity of VitaMedica Corporation. MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million on June 13, 2024.공시 • May 17Upexi, Inc. announced delayed 10-Q filingOn 05/15/2024, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 03Upexi, Inc., Annual General Meeting, Jun 10, 2024Upexi, Inc., Annual General Meeting, Jun 10, 2024, at 09:00 US Eastern Standard Time. Location: 3030 N. Rocky Point Drive, Suite 420 Tampa United States Agenda: To elect five (5) director nominees, nominated by the board of directors, for a one-year term; to ratify the appointment of b f Borgers CPA pc as independent registered public accounting firm for the fiscal year ending June 30, 2024; and to consider such other business.New Risk • Apr 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.30m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.0m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Market cap is less than US$10m (€9.30m market cap, or US$9.92m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year). Shareholders have been diluted in the past year (16% increase in shares outstanding).공시 • Apr 03Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)On April 1, 2024, Upexi, Inc. (the ‘Company’) received a letter (the ‘Nasdaq Bid Price Letter’) from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company’s common stock (the ‘Common Stock’) had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Requirement’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance (the ‘Compliance Period’). As of the date of this report, the Common Stock has not regained compliance with the Minimum Bid Price Requirement. In the event the Company does not regain compliance within the Compliance Period, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of the Company’s intention to cure the deficiency during said second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Nasdaq Bid Price Letter has no immediate effect on the listing or trading of the Common Stock. The Company intends to continue actively monitoring the bid price for its shares of Common Stock between now and the expiration of the Compliance Period and will consider all available options to resolve the deficiency including a reverse stock split, if necessary, with every intention to regain compliance with the Minimum Bid Price Requirement. In the event the Company receives notification from Nasdaq that the Common Stock is subject to delisting, the Company may appeal the Nasdaq staff’s determination before the Nasdaq Hearings Panel (the ‘Panel’). However, there can be no assurance that, in the event of such appeal, the Panel would grant the Company’s request for continued listing.Reported Earnings • Feb 15Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.17 profit in 2Q 2023)Second quarter 2024 results: US$0.12 loss per share (down from US$0.17 profit in 2Q 2023). Revenue: US$21.8m (down 19% from 2Q 2023). Net loss: US$2.44m (down 182% from profit in 2Q 2023). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 5.4% growth forecast for the Personal Products industry in Europe.Board Change • Feb 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 15+ 1 more updateUpexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023Upexi, Inc. revised preliminary and unaudited financial guidance for the first quarter ended September 30, 2023. For the year, the company expects Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.공시 • Sep 15Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog SupplementsUpexi Inc. announced LuckyTail, its pet brand and leading designer and manufacturer of pet care solutions, is expanding its latest product line with the launch of all-natural dog supplements. The supplement line will be offered via subscription and in batches, delivering the most value for pet owners' health and grooming needs. The line includes six functional formulas to address the most common concerns dog owners have including, hip & joint, calming, flea & tick, probiotic and allergy & immune issues. With a focus on quality ingredients, all chews are all-natural, human-grade, GMP certified, third-party tested and made in the USA. The line features the following all-natural, chewable supplements: Calming chews improve emotional balance, support relaxation, and relieve stress and anxiety for dogs, a perfect complement to LuckyTail's Ultimate Nail Grinder. AllerImmune chews provide immune-boosting properties and relief from common dog allergy symptoms, including decreased paw licking, itching, flea & tick, and skin irritation. Flea & tick chews are an all-natural, chemical-free solution to help prevent pesky pests.ip & Joint chews promote healthier bones and joints, increased mobility, and reduce soreness and discomfort. As dogs age, their hips and joints can cause pain and discomfort. Probiotic chews provide a safe and effective way to improve pet gut health and reduce bloating, from immune support to gut and digestive health. Skin & Coat chews give dogs a beautiful shiny coat and healthy skin. These dog coat supplements help relieve itching, improve moisturizer, and boost immunity. This launch marks the first of many product expansions LuckyTail has planned, as the brand solidifies its position as a top source to connect pet parents with their pet care needs.공시 • Sep 08Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.Amplifyir Inc. entered into an equity interest purchase agreement to acquire 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million on August 31, 2023. In addition, there is an obligation to pay Upexi 2.5% of certain advertising revenues of Interactive for a two-year period post-closing. Peter Campitiello of McCarter & English acted as legal advisor to Interactive Offers LLC. Ross Carmel of Carmel, Milazzo & Feil LLP acted as legal advisor to Amplifyir.Amplifyir Inc. completed the acquisition of 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) on August 31, 2023.New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€39.5m market cap, or US$43.5m).공시 • May 19Upexi, Inc., Annual General Meeting, Jun 26, 2023Upexi, Inc., Annual General Meeting, Jun 26, 2023, at 10:00 Eastern Daylight. Location: 17129 US Hwy 19 N Clearwater Florida United States Agenda: To elect five (5) director nominees, nominated by the board of directors, for a one-year term, such term to continue until the annual meeting of shareholders in 2024 or until such director's successors are duly elected and qualified or until their earlier resignation or removal; to ratify the appointment of b f Borgers CPA pc as independent registered public accounting firm for the fiscal year ending June 30, 2023; and to consider such other business.Reported Earnings • May 16Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)Third quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.003 loss in 3Q 2022). Revenue: US$24.2m (up 136% from 3Q 2022). Net loss: US$1.93m (loss widened US$1.88m from 3Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe.공시 • Feb 16Upexi, Inc. announced delayed 10-Q filingOn 02/15/2023, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Feb 16Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)Second quarter 2023 results: EPS: US$0.17 (up from US$0.004 in 2Q 2022). Revenue: US$27.1m (up 154% from 2Q 2022). Net income: US$2.96m (up US$2.90m from 2Q 2022). Profit margin: 11% (up from 0.6% in 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe.Recent Insider Transactions • Dec 06CEO, President & Chairman of the Board recently bought €70k worth of stockOn the 1st of December, Allan Marshall bought around 18k shares on-market at roughly €3.77 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Allan's only on-market trade for the last 12 months.Reported Earnings • Nov 17First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)First quarter 2023 results: US$0.15 loss per share (down from US$0.033 profit in 1Q 2022). Revenue: US$11.6m (up 37% from 1Q 2022). Net loss: US$2.55m (down US$3.06m from profit in 1Q 2022). Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Personal Products industry in Europe.Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO, President & Chairman of the Board Allan Marshall is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 03Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.Grove, Inc. (NasdaqCM:GRVI) signed a non-binding Letter of Intent to acquire E-Core, Inc on August 2, 2022. E- Core was acquired through Upexi. Grove plans to fund this acquisition without an additional equity offering. Grove and E-Core anticipate that the transaction will close in August 2022. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc on November 2, 202. Upexi Inc. will pay consideration in combination of cash, stock and one-to-three year notes.공시 • Oct 28+ 1 more updateBloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million on October 27, 2022. The total purchase consideration of approximately $23.5 million consisted of cash consideration of $5.5 million and $18 million of non-cash consideration. The non-cash consideration consisted of the issuance by Bloomios to Upexi of a $4.5 million senior secured convertible debenture, a $5 million secured subordinated promissory note, and shares of a newly created Series D Convertible Preferred Stock with a value of $8.5 million. The acquisition was funded in part through a senior secured convertible debenture offering with an aggregate principal amount of approximately $13,893,059 (including a 15% original issue discount) led by institutional investors. The total new investment received in connection with the senior secured convertible debenture offering was $6.25 million with the balance of the principal amount consisting of issuances to Upexi and the refinancing of previous loans. Revere Securities LLC and Spartan Capital Securities, LLC acted financial advisors to Bloomios, Inc. Bloomios, Inc. (OTCPK:BLMS) completed the acquisition of Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) on October 27, 2022.공시 • Oct 12Upexi, Inc. Files Patent for its Single Click-to-optin TechnologyUpexi Inc. announced that its SaaS Ad Tech Division, Interactive Offers, has filed a patent for its single click-to-optin technology that has fueled growth and partnerships with large publishers. The competitive landscape and higher advertising costs have forced companies to lower budgets and/or try and find new opportunities. Interactive Offers' unique technology adds value for companies by changing the way advertisers pay for leads. With this new single click-to-optin technology, advertisers will no longer be paying per click or per impression, but will be bidding on a verified lead that has opted in to receive promotions and emails for each advertiser(s).공시 • Sep 30Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023Upexi, Inc. provided revenue guidance for the Fiscal year 2023. For the period, the company estimates baseline annual revenue to be in the range of $72 to $82 million for the full fiscal year.Reported Earnings • Sep 29Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)Full year 2022 results: US$0.13 loss per share (down from US$0.25 profit in FY 2021). Revenue: US$44.6m (up 85% from FY 2021). Net loss: US$2.10m (down 172% from profit in FY 2021). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Personal Products industry in Europe.공시 • Sep 01Upexi, Inc. Appoints Anthony Bazan as Chief Operating OfficerOn August 29, 2022, Upexi, Inc. appointed Anthony Bazan as Chief Operating Officer of the Company. Mr. Bazan, age 57, joined the Company in August of 2022 as the Chief Operations Officer. Prior to joining the Company Mr. Bazan was CEO and Director of OnlineTech Stores and Group CEO and Director for Imaging Supplies Consolidation II, a Blackford Capital portfolio group. Mr. Bazan has a 30 year career in operations starting at Rockwell International, Easton Sports, Fiskars, Black & Decker, Jakks Pacific, Mega Brands, and TM International. At Mega Brands, Mr. Bazan was COO from 2008 to 2011. During his tenure Mega Brands grew $200 million in revenue and increased share price from $0.45 to $9.75. At TM International, Mr. Bazan served as CEO and Director from 2017 to 2021. During this period, Mr. Bazan was able to turn around a failing promotional products and e-commerce company, even during the height of COVID-19 when no promotional events were taking place. Mr. Bazan attended the Air Force Academy after earning both a Congressional and Senatorial nomination. A spinal injury caused him to depart the AFA early and honorably, while earning a Certificate of Completion in Engineering. Mr. Bazan continued his education gaining a BA in Economics from California State University of Northridge.Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €4.66, the stock trades at a trailing P/E ratio of 24.2x. Average forward P/E is 25x in the Personal Products industry in Europe. Total loss to shareholders of 18% over the past year.공시 • Aug 03Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc on August 2, 2022. E- Core was acquired through Upexi. Grove plans to fund this acquisition without an additional equity offering. The deal uses debt, restricted equity, and payouts in subsequent years based on revenue and EBITDA milestones. Grove and E-Core anticipate that the transaction will close in August 2022.Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to €4.86, the stock trades at a trailing P/E ratio of 26.6x. Average forward P/E is 27x in the Personal Products industry in Europe. Total returns to shareholders of 14% over the past year.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 21% share price gain to €4.51, the stock trades at a trailing P/E ratio of 23.3x. Average forward P/E is 27x in the Personal Products industry in Europe. Negligible returns to shareholders over past year.공시 • Jun 26Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value IndexGrove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value IndexValuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €3.92, the stock trades at a trailing P/E ratio of 21.7x. Average forward P/E is 26x in the Personal Products industry in Europe.Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 22% share price gain to €5.03, the stock trades at a trailing P/E ratio of 29.1x. Average forward P/E is 26x in the Personal Products industry in Europe.공시 • May 18Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Grove, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company estimated revenue at a range of $16 million to $18 million.Reported Earnings • May 17Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)Third quarter 2022 results: US$0.003 loss per share (down from US$0.071 profit in 3Q 2021). Revenue: US$10.3m (up 62% from 3Q 2021). Net loss: US$52.7k (down 105% from profit in 3Q 2021). Over the next year, revenue is forecast to grow 96%, compared to a 12% growth forecast for the industry in Germany.Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO & Chairman of the Board Allan Marshall is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Apr 21Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC on April 20, 2022. The acquisitions was made by its brand aggregation division, Upexi. The acquisition was completed with a combination of stock, cash, and debt, resulting in minimal dilution to shareholders. Cygnet has sales over $26,540,000 million in the trailing 12 months. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of Cygnet Online LLC on April 20, 2022.공시 • Apr 13Grove, Inc., Annual General Meeting, May 24, 2022Grove, Inc., Annual General Meeting, May 24, 2022, at 10:00 US Eastern Standard Time. Location: 505 Water Street, Tampa, FL 33602, Tampa Marriot Water Street Florida United States Agenda: To discuss election of directors; to discuss increase in number of shares to stock option; and to discuss ratification of appointment of independent accountants.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to €4.94, the stock trades at a trailing P/E ratio of 22.1x. Average forward P/E is 28x in the Personal Products industry in Europe.Reported Earnings • Feb 15Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: EPS: US$0.002 (down from US$0.008 in 2Q 2021). Revenue: US$10.7m (up 156% from 2Q 2021). Net income: US$64.8k (down 37% from 2Q 2021). Profit margin: 0.6% (down from 2.5% in 2Q 2021). Revenue missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 45%, compared to a 8.3% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €4.16, the stock trades at a trailing P/E ratio of 17.6x. Average forward P/E is 30x in the Personal Products industry in Europe.Valuation Update With 7 Day Price Move • Dec 08Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €3.66, the stock trades at a trailing P/E ratio of 17.3x. Average forward P/E is 29x in the Personal Products industry in Europe.Board Change • Dec 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. President Robb Hackett is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 17First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: US$8.45m (up 188% from 1Q 2021). Net income: US$511.7k (up US$1.32m from 1Q 2021). Profit margin: 6.1% (up from net loss in 1Q 2021).Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improved over the past weekAfter last week's 70% share price gain to €7.20, the stock trades at a trailing P/E ratio of 37.4x. Average forward P/E is 32x in the Personal Products industry in Europe.Reported Earnings • Sep 30Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$24.1m (up 225% from FY 2020). Net income: US$2.93m (up US$8.31m from FY 2020). Profit margin: 12% (up from net loss in FY 2020).공시 • Aug 20Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC on August 19, 2021. The contemplated acquisition is subject to completion of due diligence and definitive agreements and is expected to be completed within the next 30 days.공시 • Aug 07Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation on June 29, 2021. The parties plan to negotiate in good faith a definitive binding agreement over the next 30 days. It is anticipated that if the acquisition does ultimately close, it will be immediately accretive to Grove, being both top line and net income positive for the company. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation on August 5, 2021. Barry C. Averitt of Averitt & Alford, P.A. acted as legal advisor to Grove, Inc. Steven E. Burton of Speciale & Burton, APC acted as legal advisor to the sellers.이익 및 매출 성장 예측DB:7TQ0 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202731N/AN/A-526/30/202627N/AN/A-1313/31/202626-228-22-22N/A12/31/202525-123-18-18N/A9/30/20252155-16-16N/A6/30/202516-14-9-8N/A3/31/202517-23-2-1N/A12/31/202419-2400N/A9/30/202422-2512N/A6/30/202426-25-10N/A3/31/20241-24-6-5N/A12/31/202318-21-8-7N/A9/30/202333-15-2-1N/A6/30/202336-16-10N/A3/31/202366-200N/A12/31/202249-112N/A9/30/202230-7-9-4N/A6/30/202223-6-60N/A3/31/202224-1-25N/A12/31/2021260-15N/A9/30/202125334N/A6/30/202124323N/A3/31/202116000N/A12/31/202011-3-2-2N/A9/30/20209-5-4-3N/A6/30/20207-5-6-4N/A6/30/20192-1N/A-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 7TQ0 의 예상 수익 증가율이 절약률(1.9%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: 7TQ0 의 수익이 German 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: 7TQ0 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: 7TQ0 의 수익(연간 15.1%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 7TQ0 의 수익(연간 15.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 7TQ0의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHousehold 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 14:36종가2026/05/22 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Upexi, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Brian KinstlingerAlliance Global PartnersBrett KnoblauchCantor Fitzgerald & Co.Thomas ShinskeCantor Fitzgerald & Co.1명의 분석가 더 보기
공시 • Nov 15+ 1 more updateUpexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023Upexi, Inc. revised preliminary and unaudited financial guidance for the first quarter ended September 30, 2023. For the year, the company expects Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.
공시 • Sep 30Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023Upexi, Inc. provided revenue guidance for the Fiscal year 2023. For the period, the company estimates baseline annual revenue to be in the range of $72 to $82 million for the full fiscal year.
공시 • May 18Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Grove, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company estimated revenue at a range of $16 million to $18 million.
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • May 06+ 1 more updateUpexi, Inc., Annual General Meeting, Jun 15, 2026Upexi, Inc., Annual General Meeting, Jun 15, 2026. Location: at 3030 n. rocky point drive, suite 420, fl 33607, tampa United States
공시 • Feb 10Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million.Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Price\Range: $1.17 Discount Per Security: $0.0585 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offering
공시 • Feb 06Upexi, Inc. has filed a Follow-on Equity Offering.Upexi, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offering
공시 • Feb 05Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Jan 31Upexi, Inc. to Report Q2, 2026 Results on Feb 10, 2026Upexi, Inc. announced that they will report Q2, 2026 results on Feb 10, 2026
공시 • Dec 02Upexi, Inc. announced that it has received $10.000001 million in fundingOn December 2, 2025, Upexi, Inc. announced that it has received $ 10,000,000 in funding from issuance of common stock of the company and closed the transaction. The company raised $10,000,000 upfront with up to an additional $ 13,000,000 of aggregate gross proceeds upon the cash exercise in full of warrants of the company which adds up to $ 23,000,000 in proceeds.
공시 • Nov 26Upexi, Inc. announced that it expects to receive $10.000001 million in fundingUpexi, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor for issuance of 3,289,474 common shares at a price of $3.04 per share for gross proceeds of $10,000,000.96; and warrants to purchase up to 3,289,474 common shares on November 26, 2025. The warrants will have an exercise price of $4, will be immediately exercisable, and will expire 48 months from issuance. The closing of the offering is expected to occur on or about December 1, 2025, subject to the satisfaction of customary closing conditions.
공시 • Nov 14Upexi, Inc. (NasdaqCM:UPXI) announces an Equity Buyback for $50 million worth of its shares.Upexi, Inc. (NasdaqCM:UPXI) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of it's shares.
공시 • Nov 08Upexi, Inc. to Report Q1, 2026 Results on Nov 11, 2025Upexi, Inc. announced that they will report Q1, 2026 results on Nov 11, 2025
공시 • Oct 24Upexi, Inc. Welcomes Jon Najarian to the Upexi Advisory CommitteeUpexi, Inc. announced the addition of Jon Najarian to the Upexi Advisory Committee, joining Arthur Hayes and S?L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Market Rebellion, cementing his reputation as a market heavyweight across both professional and retail trading. He is an inductee into the U.S. Options Industry Council Hall of Fame, having received the Lifetime Contribution Award in recognition of his enduring impact on the industry. Beyond his trading acumen, Jon is a prominent media personality, frequently appearing on Fox Business, NewsMax, NewsNation, and other financial platforms, where his market analyses and actionable insights reach millions of investors. With a combination of professional credibility, entrepreneurial success, and exceptional visibility, Jon has emerged as one of the most recognized and trusted voices for both institutional and retail traders navigating complex markets.
공시 • Aug 12Upexi, Inc. Announces Establishment of Advisory CommitteeUpexi, Inc. announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek to leverage the expertise, visibility and network of the Advisory Committee by: In conjunction with the establishment of the Advisory Committee, Upexi has welcomed Arthur Hayes (Twitter: @CryptoHayes) as its first member. A former equity derivatives trader at Deutsche Bank and Citigroup, Arthur’s deep financial acumen and bold vision quickly propelled him to the forefront of the digital assets space, where he co-founded BitMEX, one of the world’s largest cryptocurrency exchanges, and revolutionized digital asset trading with the invention of the perpetual swap – the most widely-traded crypto financial product of all time. Arthur is widely regarded as a thought leader whose market insights and macroeconomic commentary are followed closely by investors around the world. His fearless approach to innovation and profound impact on the industry has cemented his legacy as one of the space’s most iconic and respected voices. Additional Advisory Committee members will be announced over the coming weeks, with Committee-related content and initiatives forthcoming over the coming year and beyond. Arthur Hayes is the CIO of Maelstrom, a family office that invests across the crypto ecosystem. He is also the co-founder of BitMEX – the first crypto unicorn. Prior to entering the crypto industry, he worked as a trader in the capital markets divisions of Deutsche Bank and Citibank. Arthur holds a Bachelors of Economics from the Wharton School of Business. He has appeared on major business news networks including Bloomberg and CNBC. He is active on X (@cryptohayes) and releases a monthly newsletter (Crypto Trader Digest) read by thousands of investors globally.
공시 • Jul 26Upexi, Inc. announced that it expects to receive $500 million in funding from A.G.P. / Alliance Global Partners Corp.Upexi, Inc announced a private placement and entered into a purchase agreement with A.G.P./Alliance Global Partners to issue common shares for aggregate gross proceeds of $500,000,000 on July 25, 2025. Pursuant to the purchase agreement, the Company shall have the right, but not the obligation, to direct the Investor to purchase the lesser of (i) $500,000,000 or (ii) the Exchange Cap, which shall be the number of shares not to exceed 19.99% of the Company’s shares of common stock, par value $0.00001 per share, outstanding on July 25, 2025, unless the Company’s stockholders have approved the issuance of Common Stock in excess of the Exchange Cap, upon satisfaction of certain terms and conditions contained in the Purchase Agreement, including, but not limited to, an effective registration statement filed with the U.S. Securities and Exchange Commission. The Common Stock will be offered pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) of Regulation D promulgated thereunder, and applicable state securities laws.
공시 • Jul 17Upexi, Inc. announced that it has received $199.828744 million in funding from Big Brain HoldingsOn July 17, 2025, Upexi, Inc closed the transaction. The company issued convertible Notes for aggregate gross proceeds of $150,000,000 in its second and final tranche. The transaction included participation from from Big brain Holdings as a lead Investor among other Institutional Investors and qualified purchasers.
공시 • Jul 13Upexi, Inc. announced that it expects to receive $49.828744 million in fundingUpexi, Inc. announces that it has entered into securities purchase agreements to issue 12,457,186 shares of common stock at a price of $4 per share for gross proceeds of $49,828,744 on July 11, 2025. The closing of the Equity Offering is expected to occur on or about July 14, 2025.
공시 • May 17Upexi, Inc. announced delayed 10-Q filingOn 05/16/2025, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 01Upexi, Inc., Annual General Meeting, Jun 16, 2025Upexi, Inc., Annual General Meeting, Jun 16, 2025. Location: 3030 n. rocky point drive, suite 420, florida 33607., tampa, United States
공시 • Apr 26Upexi, Inc. announced that it has received $99.99211 million in funding from GSR, Big Brain, White Star Capital, L.P., Delta Blockchain Fund LPOn April 24, 2025, Upexi, Inc. closed the transaction. The company issued 35,970,383 shares of common stock and 7,889,266 pre-funded warrants at a price of $2.28 per share for aggregate gross proceeds of approximately $100 million.
공시 • Apr 21Upexi, Inc. announced that it expects to receive $100 million in funding from GSR, Big Brain, White Star Capital, L.P., Delta Blockchain Fund LP and other investorsUpexi, Inc. announced that it has entered into securities purchase agreements with certain investors to issue 43,859,649 shares of common stock or pre-funded warrants at issue price of $2.28 per share for gross proceeds of $99,999,999.72 on April 21, 2025. The transaction includes participation from lead investor, GSR Markets UK Limited, Big Brain, Anagram, Delphi Ventures, White Star Capital, Maelstrom, the family office of Arthur Hayes, Hivemind, Borderless, Morgan Creek, Elune Capital, and Delta Blockchain Fund, including Austin Federa, Frank Chaparro, Joey Krug, Bartosz Lipinski, Larry Wu, and Jordan Prince, among others including Allan Marshall. The closing of the offering is expected to occur on or about April 24, 2025. The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated thereunder, or applicable state securities laws.
공시 • Nov 22Upexi Receives Notice from the Nasdaq Stock MarketUpexi, Inc. received a Non Compliance Letter from The Nasdaq Stock Market LLC due to the Company’s failure to timely file its Form 10-Q Quarterly Report for the period ended September 30, 2024, in violation of Nasdaq Listing Rule 5250(c)(1). The Company failed to timely file due to circumstances beyond its control, and intends to file its Form 10-Q Quarterly Report shortly after it is able to file its Form 10-K Annual Report. Pursuant to the Nasdaq Listing Rules, the Company has until December 20, 2024 to submit a plan to regain compliance. If the plan is accepted, an extension may be granted of up to 180 calendar days from the due date of the Initial Delinquent Filing, or April 14, 2025, to regain compliance. The Notice has no immediate effect on the listing or trading of the Company’s common stock.
공시 • Nov 15Upexi, Inc. announced delayed 10-Q filingOn 11/14/2024, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 24+ 1 more updateUpexi, Inc. to Report Fiscal Year 2024 Results on Nov 01, 2024Upexi, Inc. announced that they will report fiscal year 2024 results at 9:30 AM, US Eastern Standard Time on Nov 01, 2024
공시 • Oct 03Nasdaq Grants Additional 180 Days to Upexi to Regain Compliance with Minimum Bid Price RequirementUpexi, Inc. received a letter from The Nasdaq Stock Market LLC (Nasdaq") indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company's common stock (the Common Stock") had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance. The Common Stock did not regain compliance with the Minimum Bid Price Requirement within such period. The Company timely requested, and was granted by Nasdaq on October 1, 2024, an additional 180 calendar days to regain compliance with the Minimum Bid Price Requirement.
공시 • Oct 01Upexi, Inc. announced delayed annual 10-K filingOn 09/30/2024, Upexi, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Aug 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 07David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million on August 1, 2024. A cash consideration of $2 million will be paid by E-Core Holdings, LLC. The purchase price in the transaction was $2 million. In addition, in connection with the closing of the transaction (i) Upexi, Inc. was released as a guarantor from E-Core, Inc’s commercial loan facility, and (ii) all subordinated promissory notes issued by Upexi, Inc. in connection with the Upexi, Inc.’s initial acquisition of E-Core, Inc were cancelled and any outstanding principal and interest thereunder was deemed paid in full. On the Closing Date, (a) each Transaction Document shall be deemed null and void, and all obligations of the parties thereunder shall terminate; (b) Upexi Newco shall assign and transfer back to Upexi Newcos all of E-Core Newco’s right, title and interest in and to 4,000 shares of common stock of E-Core purchased from Upexi Newco in the Transaction (the “ E-Core Shares ”), constituting all of E-Core’s issued and outstanding securities, free and clear of any liens or encumbrances; and (c) the Consideration shall be paid in full by the Parties. Dickinson Wright PLLC acted as legal advisor to Upexi, Inc. and Korn & Kalish LLP acted as legal advisor to David Romano, Nick Romano and Eric Limont. David Romano, Nick Romano and Eric Limont completed the acquisition of E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) on August 1, 2024.
공시 • Jun 22Upexi Provides Update on Filing Form 10Q for March 31, 2024Upexi, Inc. (the Company" or Upexi") is providing shareholders with a update on filing its financial statements for the three and nine months ended March 31, 2024. On June 17, 2024, the Company received a notice from Nasdaq Listing Qualifications that since the Company has not yet filed its Form 10-Q for the period ended March 31, 2024 (the Filing"), it no longer complies with our Listing Rules (the Rules") for continued listing. Under the Rules the Company now has 60 calendar days to submit a plan to regain compliance and if we accept your plan, we can grant an exception of up to 180 calendar days from the Filing's due date, or until December 11, 2024, to regain compliance. Upexi management has discussed this with the Nasdaq and expects to file the form 10-Q for the period ended March 31, 2024 prior to the end of June 30, 2024 and once this is filed, a plan will not be necessary to regain compliance. The Nasdaq Notice Letter has no immediate effect on the listing or trading of the Company's common stock.
공시 • Jun 21Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024Upexi, Inc. announced that they will report Q3, 2024 results on Jun 24, 2024
공시 • Jun 18MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million on June 13, 2024. A cash consideration of $4 million will be paid by MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC. MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC will pay an earnout/contingent payment of $1 million promissory note and of $1 million cash. As part of consideration, $6 million is paid towards common equity of VitaMedica Corporation. MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million on June 13, 2024.
공시 • May 17Upexi, Inc. announced delayed 10-Q filingOn 05/15/2024, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 03Upexi, Inc., Annual General Meeting, Jun 10, 2024Upexi, Inc., Annual General Meeting, Jun 10, 2024, at 09:00 US Eastern Standard Time. Location: 3030 N. Rocky Point Drive, Suite 420 Tampa United States Agenda: To elect five (5) director nominees, nominated by the board of directors, for a one-year term; to ratify the appointment of b f Borgers CPA pc as independent registered public accounting firm for the fiscal year ending June 30, 2024; and to consider such other business.
New Risk • Apr 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.30m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.0m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Market cap is less than US$10m (€9.30m market cap, or US$9.92m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year). Shareholders have been diluted in the past year (16% increase in shares outstanding).
공시 • Apr 03Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)On April 1, 2024, Upexi, Inc. (the ‘Company’) received a letter (the ‘Nasdaq Bid Price Letter’) from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company’s common stock (the ‘Common Stock’) had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Requirement’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance (the ‘Compliance Period’). As of the date of this report, the Common Stock has not regained compliance with the Minimum Bid Price Requirement. In the event the Company does not regain compliance within the Compliance Period, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of the Company’s intention to cure the deficiency during said second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Nasdaq Bid Price Letter has no immediate effect on the listing or trading of the Common Stock. The Company intends to continue actively monitoring the bid price for its shares of Common Stock between now and the expiration of the Compliance Period and will consider all available options to resolve the deficiency including a reverse stock split, if necessary, with every intention to regain compliance with the Minimum Bid Price Requirement. In the event the Company receives notification from Nasdaq that the Common Stock is subject to delisting, the Company may appeal the Nasdaq staff’s determination before the Nasdaq Hearings Panel (the ‘Panel’). However, there can be no assurance that, in the event of such appeal, the Panel would grant the Company’s request for continued listing.
Reported Earnings • Feb 15Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.17 profit in 2Q 2023)Second quarter 2024 results: US$0.12 loss per share (down from US$0.17 profit in 2Q 2023). Revenue: US$21.8m (down 19% from 2Q 2023). Net loss: US$2.44m (down 182% from profit in 2Q 2023). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 5.4% growth forecast for the Personal Products industry in Europe.
Board Change • Feb 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 15+ 1 more updateUpexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023Upexi, Inc. revised preliminary and unaudited financial guidance for the first quarter ended September 30, 2023. For the year, the company expects Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.
공시 • Sep 15Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog SupplementsUpexi Inc. announced LuckyTail, its pet brand and leading designer and manufacturer of pet care solutions, is expanding its latest product line with the launch of all-natural dog supplements. The supplement line will be offered via subscription and in batches, delivering the most value for pet owners' health and grooming needs. The line includes six functional formulas to address the most common concerns dog owners have including, hip & joint, calming, flea & tick, probiotic and allergy & immune issues. With a focus on quality ingredients, all chews are all-natural, human-grade, GMP certified, third-party tested and made in the USA. The line features the following all-natural, chewable supplements: Calming chews improve emotional balance, support relaxation, and relieve stress and anxiety for dogs, a perfect complement to LuckyTail's Ultimate Nail Grinder. AllerImmune chews provide immune-boosting properties and relief from common dog allergy symptoms, including decreased paw licking, itching, flea & tick, and skin irritation. Flea & tick chews are an all-natural, chemical-free solution to help prevent pesky pests.ip & Joint chews promote healthier bones and joints, increased mobility, and reduce soreness and discomfort. As dogs age, their hips and joints can cause pain and discomfort. Probiotic chews provide a safe and effective way to improve pet gut health and reduce bloating, from immune support to gut and digestive health. Skin & Coat chews give dogs a beautiful shiny coat and healthy skin. These dog coat supplements help relieve itching, improve moisturizer, and boost immunity. This launch marks the first of many product expansions LuckyTail has planned, as the brand solidifies its position as a top source to connect pet parents with their pet care needs.
공시 • Sep 08Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.Amplifyir Inc. entered into an equity interest purchase agreement to acquire 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million on August 31, 2023. In addition, there is an obligation to pay Upexi 2.5% of certain advertising revenues of Interactive for a two-year period post-closing. Peter Campitiello of McCarter & English acted as legal advisor to Interactive Offers LLC. Ross Carmel of Carmel, Milazzo & Feil LLP acted as legal advisor to Amplifyir.Amplifyir Inc. completed the acquisition of 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) on August 31, 2023.
New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€39.5m market cap, or US$43.5m).
공시 • May 19Upexi, Inc., Annual General Meeting, Jun 26, 2023Upexi, Inc., Annual General Meeting, Jun 26, 2023, at 10:00 Eastern Daylight. Location: 17129 US Hwy 19 N Clearwater Florida United States Agenda: To elect five (5) director nominees, nominated by the board of directors, for a one-year term, such term to continue until the annual meeting of shareholders in 2024 or until such director's successors are duly elected and qualified or until their earlier resignation or removal; to ratify the appointment of b f Borgers CPA pc as independent registered public accounting firm for the fiscal year ending June 30, 2023; and to consider such other business.
Reported Earnings • May 16Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)Third quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.003 loss in 3Q 2022). Revenue: US$24.2m (up 136% from 3Q 2022). Net loss: US$1.93m (loss widened US$1.88m from 3Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe.
공시 • Feb 16Upexi, Inc. announced delayed 10-Q filingOn 02/15/2023, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Feb 16Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)Second quarter 2023 results: EPS: US$0.17 (up from US$0.004 in 2Q 2022). Revenue: US$27.1m (up 154% from 2Q 2022). Net income: US$2.96m (up US$2.90m from 2Q 2022). Profit margin: 11% (up from 0.6% in 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe.
Recent Insider Transactions • Dec 06CEO, President & Chairman of the Board recently bought €70k worth of stockOn the 1st of December, Allan Marshall bought around 18k shares on-market at roughly €3.77 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Allan's only on-market trade for the last 12 months.
Reported Earnings • Nov 17First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)First quarter 2023 results: US$0.15 loss per share (down from US$0.033 profit in 1Q 2022). Revenue: US$11.6m (up 37% from 1Q 2022). Net loss: US$2.55m (down US$3.06m from profit in 1Q 2022). Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Personal Products industry in Europe.
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO, President & Chairman of the Board Allan Marshall is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 03Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.Grove, Inc. (NasdaqCM:GRVI) signed a non-binding Letter of Intent to acquire E-Core, Inc on August 2, 2022. E- Core was acquired through Upexi. Grove plans to fund this acquisition without an additional equity offering. Grove and E-Core anticipate that the transaction will close in August 2022. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc on November 2, 202. Upexi Inc. will pay consideration in combination of cash, stock and one-to-three year notes.
공시 • Oct 28+ 1 more updateBloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million on October 27, 2022. The total purchase consideration of approximately $23.5 million consisted of cash consideration of $5.5 million and $18 million of non-cash consideration. The non-cash consideration consisted of the issuance by Bloomios to Upexi of a $4.5 million senior secured convertible debenture, a $5 million secured subordinated promissory note, and shares of a newly created Series D Convertible Preferred Stock with a value of $8.5 million. The acquisition was funded in part through a senior secured convertible debenture offering with an aggregate principal amount of approximately $13,893,059 (including a 15% original issue discount) led by institutional investors. The total new investment received in connection with the senior secured convertible debenture offering was $6.25 million with the balance of the principal amount consisting of issuances to Upexi and the refinancing of previous loans. Revere Securities LLC and Spartan Capital Securities, LLC acted financial advisors to Bloomios, Inc. Bloomios, Inc. (OTCPK:BLMS) completed the acquisition of Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) on October 27, 2022.
공시 • Oct 12Upexi, Inc. Files Patent for its Single Click-to-optin TechnologyUpexi Inc. announced that its SaaS Ad Tech Division, Interactive Offers, has filed a patent for its single click-to-optin technology that has fueled growth and partnerships with large publishers. The competitive landscape and higher advertising costs have forced companies to lower budgets and/or try and find new opportunities. Interactive Offers' unique technology adds value for companies by changing the way advertisers pay for leads. With this new single click-to-optin technology, advertisers will no longer be paying per click or per impression, but will be bidding on a verified lead that has opted in to receive promotions and emails for each advertiser(s).
공시 • Sep 30Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023Upexi, Inc. provided revenue guidance for the Fiscal year 2023. For the period, the company estimates baseline annual revenue to be in the range of $72 to $82 million for the full fiscal year.
Reported Earnings • Sep 29Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)Full year 2022 results: US$0.13 loss per share (down from US$0.25 profit in FY 2021). Revenue: US$44.6m (up 85% from FY 2021). Net loss: US$2.10m (down 172% from profit in FY 2021). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Personal Products industry in Europe.
공시 • Sep 01Upexi, Inc. Appoints Anthony Bazan as Chief Operating OfficerOn August 29, 2022, Upexi, Inc. appointed Anthony Bazan as Chief Operating Officer of the Company. Mr. Bazan, age 57, joined the Company in August of 2022 as the Chief Operations Officer. Prior to joining the Company Mr. Bazan was CEO and Director of OnlineTech Stores and Group CEO and Director for Imaging Supplies Consolidation II, a Blackford Capital portfolio group. Mr. Bazan has a 30 year career in operations starting at Rockwell International, Easton Sports, Fiskars, Black & Decker, Jakks Pacific, Mega Brands, and TM International. At Mega Brands, Mr. Bazan was COO from 2008 to 2011. During his tenure Mega Brands grew $200 million in revenue and increased share price from $0.45 to $9.75. At TM International, Mr. Bazan served as CEO and Director from 2017 to 2021. During this period, Mr. Bazan was able to turn around a failing promotional products and e-commerce company, even during the height of COVID-19 when no promotional events were taking place. Mr. Bazan attended the Air Force Academy after earning both a Congressional and Senatorial nomination. A spinal injury caused him to depart the AFA early and honorably, while earning a Certificate of Completion in Engineering. Mr. Bazan continued his education gaining a BA in Economics from California State University of Northridge.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €4.66, the stock trades at a trailing P/E ratio of 24.2x. Average forward P/E is 25x in the Personal Products industry in Europe. Total loss to shareholders of 18% over the past year.
공시 • Aug 03Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc on August 2, 2022. E- Core was acquired through Upexi. Grove plans to fund this acquisition without an additional equity offering. The deal uses debt, restricted equity, and payouts in subsequent years based on revenue and EBITDA milestones. Grove and E-Core anticipate that the transaction will close in August 2022.
Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to €4.86, the stock trades at a trailing P/E ratio of 26.6x. Average forward P/E is 27x in the Personal Products industry in Europe. Total returns to shareholders of 14% over the past year.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 21% share price gain to €4.51, the stock trades at a trailing P/E ratio of 23.3x. Average forward P/E is 27x in the Personal Products industry in Europe. Negligible returns to shareholders over past year.
공시 • Jun 26Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value IndexGrove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €3.92, the stock trades at a trailing P/E ratio of 21.7x. Average forward P/E is 26x in the Personal Products industry in Europe.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 22% share price gain to €5.03, the stock trades at a trailing P/E ratio of 29.1x. Average forward P/E is 26x in the Personal Products industry in Europe.
공시 • May 18Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Grove, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company estimated revenue at a range of $16 million to $18 million.
Reported Earnings • May 17Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)Third quarter 2022 results: US$0.003 loss per share (down from US$0.071 profit in 3Q 2021). Revenue: US$10.3m (up 62% from 3Q 2021). Net loss: US$52.7k (down 105% from profit in 3Q 2021). Over the next year, revenue is forecast to grow 96%, compared to a 12% growth forecast for the industry in Germany.
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO & Chairman of the Board Allan Marshall is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Apr 21Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC on April 20, 2022. The acquisitions was made by its brand aggregation division, Upexi. The acquisition was completed with a combination of stock, cash, and debt, resulting in minimal dilution to shareholders. Cygnet has sales over $26,540,000 million in the trailing 12 months. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of Cygnet Online LLC on April 20, 2022.
공시 • Apr 13Grove, Inc., Annual General Meeting, May 24, 2022Grove, Inc., Annual General Meeting, May 24, 2022, at 10:00 US Eastern Standard Time. Location: 505 Water Street, Tampa, FL 33602, Tampa Marriot Water Street Florida United States Agenda: To discuss election of directors; to discuss increase in number of shares to stock option; and to discuss ratification of appointment of independent accountants.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to €4.94, the stock trades at a trailing P/E ratio of 22.1x. Average forward P/E is 28x in the Personal Products industry in Europe.
Reported Earnings • Feb 15Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: EPS: US$0.002 (down from US$0.008 in 2Q 2021). Revenue: US$10.7m (up 156% from 2Q 2021). Net income: US$64.8k (down 37% from 2Q 2021). Profit margin: 0.6% (down from 2.5% in 2Q 2021). Revenue missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 45%, compared to a 8.3% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €4.16, the stock trades at a trailing P/E ratio of 17.6x. Average forward P/E is 30x in the Personal Products industry in Europe.
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €3.66, the stock trades at a trailing P/E ratio of 17.3x. Average forward P/E is 29x in the Personal Products industry in Europe.
Board Change • Dec 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. President Robb Hackett is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 17First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: US$8.45m (up 188% from 1Q 2021). Net income: US$511.7k (up US$1.32m from 1Q 2021). Profit margin: 6.1% (up from net loss in 1Q 2021).
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improved over the past weekAfter last week's 70% share price gain to €7.20, the stock trades at a trailing P/E ratio of 37.4x. Average forward P/E is 32x in the Personal Products industry in Europe.
Reported Earnings • Sep 30Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$24.1m (up 225% from FY 2020). Net income: US$2.93m (up US$8.31m from FY 2020). Profit margin: 12% (up from net loss in FY 2020).
공시 • Aug 20Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC on August 19, 2021. The contemplated acquisition is subject to completion of due diligence and definitive agreements and is expected to be completed within the next 30 days.
공시 • Aug 07Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation on June 29, 2021. The parties plan to negotiate in good faith a definitive binding agreement over the next 30 days. It is anticipated that if the acquisition does ultimately close, it will be immediately accretive to Grove, being both top line and net income positive for the company. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation on August 5, 2021. Barry C. Averitt of Averitt & Alford, P.A. acted as legal advisor to Grove, Inc. Steven E. Burton of Speciale & Burton, APC acted as legal advisor to the sellers.